Santarus Inc

Santarus — Investor Day (April 2013)

114 slides from Santarus's investor day presentation, Apr 11, 2013

  1. Slide 1: Investor and Analyst Day April 11th 2013

    NASDAQ: SNTS Investor and Analyst Day April 11th 2013

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation may include forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its plans o

  3. Slide 3: Agenda

    Agenda Welcome Martha L. Hough, Vice President, Finance and Investor Relations, Santarus, Inc. Strategic Overview Gerald T. Proehl, President, Chief Executive Officer & Director, Santarus, Inc. Commercial Update William C. Denby, Senior Vice President, Commercial Operations, Santarus, Inc. Overview

  4. Slide 4: Agenda - Continued

    Agenda - Continued Uceris(tm) Launch Update Thomas J. Joyce, Vice President, Marketing and National Accounts, Santarus, Inc. Pipeline Overview Wendell Wierenga Ph.D., Executive Vice President, Research and Development, Santarus, Inc. Ruconest(r) Mark C. Totoritis, M.D., Senior Vice President, Clinic

  5. Slide 5: Strategic Overview

    Strategic Overview Gerald T. Proehl President, Chief Executive Officer & Director Santarus, Inc.

  6. Slide 6: Investment Highlights

    Investment Highlights Profitable specialty biopharmaceutical company with a focus on proprietary products Attractive mix of commercial and development opportunities Recent launch of Uceris(tm) (budesonide) for induction of remission in patients with active, mild to moderate ulcerative colitis Court

  7. Slide 7: Mix of Commercial & Development Opportunities

    Mix of Commercial & Development Opportunities 7 Focus on proprietary products for physician specialists Balancing investments in R&D and SG&A to achieve meaningful, sustainable growth in revenues and profits Sales potential of ~$650M - $750M Gastroenterology Uceris(tm) Zegerid(r) Type 2 diabetes Glu

  8. Slide 8: Specialty Focus - Leverage Commercial Investment

    Specialty Focus - Leverage Commercial Investment 8 Near term 2013 Medium term Long term Endocrinologists & Selected PCPs (150 reps) Glumetza(r), Cycloset(r), Fenoglide(r) Rheumatologists (30 reps) SAN-300 Gastroenterologists (85 reps) Uceris(tm), Zegerid(r) Rifamycin SV MMX, SAN-300 Allergists/ Immu

  9. Slide 9: Financial Focus - Increase Shareholder Value

    Financial Focus - Increase Shareholder Value 9 Leverage sales organization Increase sales per rep Increase revenue Decrease SG&A as % of revenue Maintain R&D as % of revenue Increase profits & cash flow Invest for future growth

  10. Slide 10: Growth Strategies

    Growth Strategies Maximize value of existing portfolio through additional formulations or indications Continue to seek new marketed or late-stage development products through license or acquisition, including company acquisitions Gastroenterology Endocrinology Other selected specialties Plan to add

  11. Slide 11: 2012 Total Revenues

    2012 2011 2012 2011 Product sales, net Glumetza(r) $ 42.6 $ 28.5 $ 145.0 $ 36.4 Zegerid(r) 20.8 9.4 48.0 43.3 Cycloset(r) 4.5 3.8 14.5 8.5 Fenoglide(r) 1.5 - 7.1 - Total product sales, net 69.4 41.7 214.6 88.2 Other revenue 0.8 0.9 3.4 30.6 Total revenues $ 70.2 $ 42.6 $ 218.0 $ 118.8 2012 Total Rev

  12. Slide 12: Financial Results

    Three Months Ended Dec 31, Cash, cash equivalents & short-term investments of $94.7 million at December 31, 2012, an increase of $36.1 million during the year 2012 Financial Results (Unaudited) 12 Year Ended Dec 31, ($ Millions) Except per share amounts 2012 2011 2012 2011 Total revenues $ 70.2 $ 42

  13. Slide 13: 2010-2012 Financial Results and 2013 Estimates

    2010 - 2012 Financial Results and 2013 Estimates 13 **Midpoint of 2013 financial outlook provided on March 4, 2013 ** ** $ Millions * * Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of adjusted EBITDA to GAAP net income can be found at the end of this presentation.

  14. Slide 14: Commercial Update

    Commercial Update William C. Denby Senior Vice President, Commercial Operations, Santarus, Inc.

  15. Slide 15: Sales Force Product Mix

    Sales Force Product Mix 15 235 Sales Reps Primary Care Physicians Endocrinologists Glumetza(r) Glumetza Cycloset(r) Cycloset Fenoglide(r)/ Zegerid* Fenoglide Gastroenterologists Uceris(tm) Zegerid(r) *Fenoglide/Zegerid to select primary care physicians based on prescribing patterns

  16. Slide 16: Zegerid advertisement

    ACID CONTROL THAT HOLDS STRONG Use ZEGERID for strong, long-lasting,

  17. Slide 17: Zegerid

    Zegerid(r) 17 Source: IMS Healthcare NPA Par Pharmaceutical ceased generic distribution after appellate court ruling in favor of Santarus in Sept 2012 Jury trial to determine damages scheduled for November 2014 Patents expire in July 2016 Net sales of $20.8 million in Zegerid brand/AG in 4Q 2012 Ind

  18. Slide 18: Glumetza advertisement

    GLUMETZA®: Unique, controlled delivery may improve tolerability and help more patients get to A1C goal Sets Gitte rer HO eet reste) Techy, Tle, and AC onl GLUMETZA ia biguanides a dnt at and exit imo goa catalina wth Iype 2 dabetes melt prt eto lt x Wooten pe | Saba or bebo Pas wn. pest a ty raining

  19. Slide 19: Glumetza

    Glumetza(r) 19 Source: IMS Health, Weekly NPA Once-daily, extended-release oral tablet Controlled delivery may improve GI tolerability and allow more patients to reach A1C goal 24% TRx growth in 4Q 2012 vs. prior year period $42.6 million net sales in 4Q 2012 Differentiated product with features wel

  20. Slide 20: Cycloset advertisement

    CYCLOSET: Improved glycemic control with a demonstrated CV safety profile Important ate Information CYCLOSET is indicated as an adjunct to diet and exercise to improve lycemic contralin adits with type 2 ciabetes melitus. Pie ss war hos como fol resign ‘tomato Te nos cormon ates rst arenas, fatigue,

  21. Slide 21: Cycloset

    Cycloset(r) 21 First and only centrally acting, oral type 2 diabetes product Unique formulation of bromocriptine Consistent A1C control Demonstrated cardiovascular safety profile with 52% relative risk reduction in MACE* in pivotal clinical study 49% TRx growth in 4Q 2012 vs. prior year period 4Q 20

  22. Slide 22: Fenoglide advertisement

    Pol Glide into lipid control —‘Fenoglide (fenofibrate) tablets 0.mg& 40mg FENOGLIDE is indicated as ‘an adjunct to diet for patents with hyperipidemia; mixed dyslipidemia, or hypertrigyceridemia. Please see ww fenoglde.com for fll prescribing and safety information, The most common adverse reactions

  23. Slide 23: Fenoglide

    Fenoglide(r) 23 Indicated for the treatment of high cholesterol Source: IMS Health, Weekly NPA High cholesterol is a co-morbid condition frequently associated with type 2 diabetes Strong overlap with current called-on physicians Promotionally sensitive Net sales of $1.5 million reported by Santarus

  24. Slide 24: 2013 Commercial Goals

    2013 Commercial Goals Successful launch of Uceris(tm) ? Key growth driver and high priority Positive early feedback from physicians and managed care Stop decline of Zegerid(r) prescriptions Continue to grow Glumetza(r), Cycloset(r) and Fenoglide(r) 24

  25. Slide 25: Overview of Ulcerative Colitis and Treatment Perspectives

    Overview of Ulcerative Colitis and Treatment Perspectives William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center

  26. Slide 26: Ulcerative Colitis - Endoscopic Spectrum of Severity

    Ulcerative Colitis - Endoscopic Spectrum of Severity Normal Moderate Mild Severe 26

  27. Slide 27: Anatomic Extent of UC vs Crohn's Disease

    Anatomic Extent of UC vs Crohn's Disease Ulcerative Colitis Crohn's Disease Pancolitis Proctitis Left-sided Upper gut 10-15% Small bowel alone 33% Ileocolonic 45% Colon alone 20% 27

  28. Slide 28: Estimates of IBD Prevalence - North America

    Estimates of IBD Prevalence - North America Location Prevalence Date UC Prevalence Crohn's Prevalence Olmsted County, MN Jan 1, 2005 273 222 Manitoba 1998 - 2000 248 271 Canada, 5-province 1998 - 2000 194 234 9 HMO (CCFA/CDC) 1999 - 2001 191 129 PharMetrics 2003 - 04 238 201 Ingle SB, et al. Gastroe

  29. Slide 29: Cumulative Risk of Colectomy Among UC Patients

    0 East 0.5 Cumulative Risk of Colectomy Among 378 UC Patients Olmsted County, 1940-2001 Cumulative incidence (%) Years from UC diagnosis Dhillon S, Sandborn WJ: Am J Gastroenterol, 2005 No. at risk 378 281 217 160 108 70 44 29

  30. Slide 30: Risk of Colorectal Cancer in UC: Meta-Analysis

    Risk of Colorectal Cancer in UC: Meta-Analysis Cumulative probability (%) Time from diagnosis (years) Eaden: Gut 48:526, 2001 0 50 100 150 200 250 300 350 400 450 500 East 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 UC Control 30

  31. Slide 31: Unmet Need In UC

    Disease Severity at Presentation 5-ASA Corticosteroid Anti-TNF Surgery 5-ASA/Thiopurine 5-ASA Anti-TNF Thiopurine Induction Maintenance Mild Moderate Severe Unmet Need In UC 31 Kornbluth and Sacher, Am J Gastroenterol 2010; 105: 501-523

  32. Slide 32: Steroids in UC

    Steroids in UC Rectal Conventional steroids Budesonide Oral Conventional steroids Budesonide Intravenous 32

  33. Slide 33: Conventional Corticosteroids

    Conventional Corticosteroids

  34. Slide 34: Oral Cortisone: Clinical Response and Remission at 6 Weeks

    Oral Cortisone: Mild-to-Severe Active UC: Clinical Response and Remission at 6 Weeks Truelove & Witts, BMJ 1954; 2: 375-8 †Clinical response defined as improved or clinical remission *Clinical remission defined as 1 or 2 stools / day without blood ***p<0.001 vs placebo *** *** † 34

  35. Slide 35: Oral Cortisone: Mucosal Healing at 6 Weeks

    Truelove & Witts, BMJ 1954; 2: 375-8 Oral Cortisone: Mild-to-Severe Active UC: Mucosal Healing at 6 Weeks *Defined as normal or near normal (slight hyperemia or granularity) mucosa *p=0.02 vs placebo * Patients (%) 35

  36. Slide 36: Corticosteroid Toxicity

    Corticosteroid Toxicity Moon face Acne Ecchymoses Hypertension Hirsutism Petechial bleeding Striae Diabetes Infection Osteonecrosis Osteoporosis Myopathy Cataracts Glaucoma Psychosis Glucocorticoid receptors are present on almost all human cells which explains the diverse side effects of corticoster

  37. Slide 37: Budesonide

    Budesonide

  38. Slide 38: Corticosteroid Pharmacokinetics

    Corticosteroid Pharmacokinetics Derendorf, Respir Med 1997; 91(Suppl.): A22-8 Systemic glucocorticoids Topical glucocorticoids Clearance (L/h) Oral bioavailability (%) Hydrocortisone Prednisolone Triamcinolone acetonide Budesonide Flunisolide Fluticasone propionate Methylprednisolone Dexametasone 10

  39. Slide 39: Budesonide Metabolism and Characteristics

    Budesonide Metabolism and Characteristics ~90% metabolism in the liver ~10% budesonide Rectal budesonide enema Oral budesonide Budesonide characteristics non-halogenated corticosteroid, highly lipophilic good tissue penetration 9x greater receptor binding than dexamethesone rapidly absorbed in GI tr

  40. Slide 40: Oral Forms of Budesonide

    Oral Forms of Budesonide Controlled ileal-release (CIR): Entocort(r) EC1 Enteric-coated granules that release at pH >5.5 Majority absorbed in ileum and cecum (69%, 95% CI: 50-84%) Indication: Treatment of acute mild-to-moderate CD, involving ileum and / or ascending colon, maintenance of clinical re

  41. Slide 41: Multi-Matrix system (MMX)

    Multi-Matrix system (MMX(r)) Multi-Matrix system (MMX(r)) - a unique technology targets drug delivery to entire colon; the site of UC potential for efficacy of conventional steroid, while minimizing systemic side-effects MMX(r) technology has previously been successfully applied to IBD (Lialda(r)) H

  42. Slide 42: Pharmaco-scintigraphy Study Evaluating Uceris

    Pharmaco-scintigraphy Study Evaluating Uceris(tm) (budesonide MMX(r)) Two Phase I studies, each with 12 healthy males Gastrointestinal transit of 152Sm-labeled Uceris 9 mg tablets evaluated by pharmaco-scintigraphy Brunner et al, Brit J Clin Pharmacol 2006; 61: 31-38 Scintigraphic image Dispersion o

  43. Slide 43: Uceris Comparative Pharmacokinetics to Entocort EC

    Uceris(tm) Comparative Pharmacokinetics to Entocort(r) EC Bioavailability profile of Uceris 9 mg tablets compared to a controlled ileal-release formulation, Entocort(r) EC 9 mg (3 x 3 mg) capsules in healthy volunteers. Single oral dose Uceris not bioequivalent to Entocort EC Time (hours) 0 500 1000

  44. Slide 44: Uceris CORE I and II: Study Design

    Uceris(tm) CORE I and II: Study Design Sandborn et al, Gastroenterology 2012; 143:1218-1226; Travis S et al, Gut 2013;epub ahead of print Uceris(tm) 9mg Uceris 6mg 44

  45. Slide 45: Ulcerative Colitis Disease Activity Index (UCDAI)

    Ulcerative Colitis Disease Activity Index (UCDAI) 45

  46. Slide 46: Primary Efficacy Endpoint

    Primary Efficacy Endpoint Induction of Clinical and Endoscopic Remission 46

  47. Slide 47: Clinical and Endoscopic Remission at Week 8

    Uceris(tm) for Active Ulcerative Colitis: Clinical and Endoscopic Remission at Week 8 Sandborn et al, Gastroenterology 2012; 143:1218-1226 Travis S et al, Gut 2013;epub ahead of print Sandborn et al, Am J Gastroenterology 2011;106 (Suppl):S485 *Statistically significant (p<0.025) ***Statistically si

  48. Slide 48: Other Clinical Endpoints

    Other Clinical Endpoints Clinical improvement A reduction of 3 points or more in UCDAI from baseline at week 8 Endoscopic improvement A ^ 1 point improvement in the mucosal appearance subscore of UCDAI from baseline to week 8 Symptom resolution UCDAI of 0 for rectal bleeding and stool frequency at w

  49. Slide 49: Uceris CORE I & II Pooled Data

    Uceris(tm) CORE I & II Pooled Data 49 The Cochran-Mantel-Haenszel test was used to compare active treatment and placebo stratifying by study. *Significant at ^=0.025; **Significant at ^=0.05. Adapted from Sandborn et al, American Journal of Gastroenterology. 2011;106 (Suppl 2):S-485

  50. Slide 50: Pooled Safety Data Analysis

    Pooled Safety Data Analysis: Side Effects of Uceris(tm) in Patients with Active UC Glucocorticoid Effect Placebo N=258 n (%) Uceris 9 mg N=255 n (%) Asacol(r) N=127 n (%) Entocort(r) EC N=126 n (%) Overall 27 (10.5) 26 (10.2) 15 (11.8) 17 (13.5) Moon face 4 (1.6) 3 (1.2) 2 (1.6) 2 (1.6) Striae rubra

  51. Slide 51: Conclusions

    Conclusions Ulcerative colitis is a chronic inflammatory bowel disease which is limited to the colon There are approximately 700,000 patients with ulcerative colitis in the United States Current treatment options are mesalamine, prednisone, immunosuppressives (azathioprine/6-mercaptopurine) and anti

  52. Slide 52: Uceris Launch Update

    Uceris(tm) Launch Update Thomas J. Joyce Vice President, Marketing and National Accounts, Santarus, Inc.

  53. Slide 53: Uceris

    Q UCERIS (Dudesonie) extended release tates

  54. Slide 54: Uceris FDA Approval and Launch

    Uceris(tm) 54 FDA approved on January 14, 2013 for induction of remission in patients with active, mild to moderate ulcerative colitis Commercial launch commenced mid-February, 2013 Ulcerative colitis, an inflammatory bowel disease (IBD), affects approximately 700,000 patients in U.S. Limited therap

  55. Slide 55: Established Therapies for Mild to Moderate Ulcerative Colitis

    Established Therapies for Mild to Moderate Ulcerative Colitis 55 Step-up according to severity at presentation or failure at prior step 5-ASA Systemic Corticosteroids Anti-TNF^ Disease severity at presentation 5-ASA / Thiopurine 5-ASA Anti-TNF^ Induction Maintenance Cyclosporine Thiopurine Severe Mo

  56. Slide 56: Selected IBD Products - U.S. TRx and Sales Trends

    Selected IBD Products - U.S. 56 TRx and IMS Sales Trends - February 2013 * Generic version of Entocort EC launched in June 2011.

  57. Slide 57: Uceris: MMX Technology Targets the Full Length of the Colon

    Uceris(tm) : MMX(r) Technology Allows Budesonide to Target the Full Length of the Colon Uceris (budesonide) Uceris is indicated for the induction of remission in patients with active, mild to moderate UC Target: Full length of colon MMX technology: Pill dissolves at pH ^7.0, the approximate pH level

  58. Slide 58: Key Uceris Customers

    Key Uceris(tm) Customers 58 Prescribing GEs Pharmacy Patients KOLs Payers

  59. Slide 59: Key Uceris Customers: Prescribing GEs

    Pharmacy Pharmacy Key Uceris(tm) Customers 59 Prescribing GEs KOL Payers Patients Patients Prescribing GEs ~7,500 high potential Gastroenterologists Primary focus of Sales Force

  60. Slide 60: Physician Reactions to Uceris

    Physician Reactions to Uceris(tm) Very positive reactions to Uceris messages Uceris story is logical Putting together two familiar ideas - budesonide and MMX Clear need for this product - "I've been waiting for someone to formulate budesonide for UC" Key drivers of usage: efficacy, budesonide experi

  61. Slide 61: Uceris website

    POWER YOUR PATIENTS CAN HANDLE @® Targeted Delivery » i) Efficacy » @® Safety > ® Convenience/Affordability » ® Important Safety Information > ERIS™ isa gucocaticostrod indeated forthe induction of remission n patents wih @

  62. Slide 62: Uceris Sales Rep Promotion

    Uceris(tm) Sales Rep Promotion 62

  63. Slide 63: Uceris Advertising

    Uceris™ Advertising Now Approved 2 UCERIS™ Power your patients can handle NOW APPROVED FOR ACTIVE, MILD-TO-MODERATE VSANTARLS

  64. Slide 64: Key Uceris Customers: KOLs

    Pharmacy Pharmacy Key Uceris(tm) Customers Prescribing GEs KOL 300-400 top National, Regional and Local Key Opinion Leaders Primary focus of MSL team Payers Patients Patients KOLs Prescribing GEs ~7,500 high potential Gastroenterologists Primary focus of Sales Force Prescribing GEs 64

  65. Slide 65: Speaker Programs

    Speaker Programs | asain soa trina we leconerence ‘th UCERIS Natal Thoght ears 2013 UCERIS: ee nyse se

  66. Slide 66: Key Uceris Customers: Payers

    Pharmacy Pharmacy Key Uceris(tm) Customers 66 Prescribing GEs KOL 300-400 top National, Regional and Local Key Opinion Leaders Primary focus of MSL team Payers Patients Patients Payers KOL Prescribing GEs ~7,500 high potential Gastroenterologists Primary focus of Sales Force KOLs Prescribing GEs Gov

  67. Slide 67: Managed Care - Reimbursement & Coverage

    Managed Care - Reimbursement & Coverage Account managers and medical science liaisons in active discussions with managed care organizations across the U.S. Uceris(tm) generally covered with a Tier 3 copay Implemented $25 eVoucher program for patients with commercial insurance to increase access and

  68. Slide 68: Key Uceris Customers: Patients

    Key Uceris(tm) Customers 68 Prescribing GEs KOL 300-400 top National, Regional and Local Key Opinion Leaders Primary focus of MSL team Payers ~700K UC patients Payers KOL Prescribing GEs ~7,500 high potential Gastroenterologists Primary focus of Sales Force Payers KOLs Prescribing GEs Government: Me

  69. Slide 69: Internet Based Patient Programs

    Internet Based Patient Programs 69

  70. Slide 70: Outreach to Patients on Uceris.com

    Outreach to Patients on Uceris.com 70

  71. Slide 71: Key Uceris Customers: Pharmacy

    Pharmacy Key Uceris(tm) Customers 71 Prescribing GEs KOL 300-400 top National, Regional and Local Key Opinion Leaders Primary focus of MSL team Payers Government: Medicaid, Medicare, Department of Defense, Veterans Affairs Commercial: Insurance Companies Patients ~700K UC patients Wholesalers and ~5

  72. Slide 72: Uceris Weekly Prescription and Prescriber Trends

    Uceris(tm) Weekly Prescription and Prescriber Trends 72 Source: IMS Health, Weekly NPA

  73. Slide 73: Pipeline Overview

    Pipeline Overview Wendell Wierenga, Ph.D. Executive Vice President, Research and Development, Santarus, Inc.

  74. Slide 74: Santarus Development Pipeline

    Santarus Development Pipeline Product /Candidate Phase I Phase II Phase III Uceris(tm) (add-on to 5-ASA) Uceris (pediatric) Ruconest(r) (acute treatment - HAE) Ruconest (prophylaxis - HAE) Ruconest (acute pancreatitis) Rifamycin SV MMX(r) (TD) SAN-300 (RA) SAN-300 (IBD) CONTRIBUTE study BLA planned

  75. Slide 75: Development Pipeline and Potential Exclusivity

    Development Pipeline and Potential Exclusivity 2013 // 2020 2021 2022 2023 2024 2025 * Uceris is approved for induction of remission in patients with active, mild to moderate UC ** Anticipate pre-IND meeting with FDA †Ruconest and SAN-300 are biologics and expected to be eligible for 12 years data e

  76. Slide 76: Uceris Post-Approval Clinical Studies

    Uceris? Post-Approval Clinical Studies CONTRIBUTE (Phase IIIb): induction in active, mild/moderate UC not adequately controlled on 5-ASA Multicenter, randomized, double-blind, placebo-controlled 2 arm: Uceris 9mg + 5-ASA vs placebo + 5-ASA 500 patients (1:1 randomization) in North America, Europe, B

  77. Slide 77: Rifamycin SV MMX

    Rifamycin SV MMX(r) New chemical entity in U.S. Rifamycin SV has 20 year history of use in Europe in IV/IM forms Clinical activity in infectious diarrhea appears comparable to Xifaxan(r) (rifaximin) U.S. patents expire 2020 and 2025 Positive top-line results in Phase III clinical study for treatment

  78. Slide 78: Rifamycin SV MMX Phase III Study

    Rifamycin SV MMX(r) Multicenter, randomized, double-blind, placebo-controlled Phase III clinical study enrolled 264 patients in Mexico and Guatemala Patients randomized 3:1 (active:placebo) Evaluated 400mg BID (800mg per day) vs placebo over 3 days for traveler's diarrhea Primary endpoint - time to

  79. Slide 79: Anti-VLA-1: SAN-300

    Anti-VLA-1: SAN-300 Novel approach to autoimmune/inflammatory disease therapy The Target Integrin VLA-1 (a1b1 integrin) Major collagen receptor Immune cell expression primarily on activated T cells and monocytes VLA-1 mediates migration, retention and proliferation of these cells at sites of inflamm

  80. Slide 80: Efficacy in Multiple Animal Models

    Efficacy in Multiple Animal Models Rheumatoid Arthritis (RA) Inflammatory Bowel Disease (IBD) Psoriasis Corneal Transplant Kidney Disease (Nephritis) Asthma Others 80

  81. Slide 81: SAN-300 Phase I Clinical Study

    SAN-300 Phase I Clinical Study Single ascending dose, placebo-controlled design (N=66 healthy subjects) Assessment of intravenous (N=33 Active) and subcutaneous (N=12 Active) administration Preliminary safety findings IV (0.03-2.0 mg/kg): mild/moderate infusion reactions (flu-like symptoms) SC (2.0-

  82. Slide 82: SAN-300 Clinical Strategy

    SAN-300 Clinical Strategy Rheumatoid Arthritis Phase IIa placebo-controlled, multiple ascending dose study Anticipate initiation Q4 2013 Inflammatory Bowel Disease Phase II randomized, double-blind, placebo-controlled study Anticipate initiation prior to completion of Phase IIa RA study 82

  83. Slide 83: Ruconest (Recombinant human C1 esterase inhibitor)

    RUCONEST(r) (Recombinant human C1 esterase inhibitor) Mark C. Totoritis, M.D. Senior Vice President, Clinical Research Santarus, Inc.

  84. Slide 84: Hereditary Angioedema (HAE)

    Hereditary Angioedema (HAE) *Based on company estimates 84 Rare and potentially life-threatening disorder Caused by mutations in the gene coding for C1 esterase inhibitor (C1INH) Deficient C1INH function leads to acute attacks of angioedema in HAE patients Results in unpredictable and recurrent atta

  85. Slide 85: U.S. HAE Treatments - Evolving to Acute Therapies

    U.S. HAE Treatments - Evolving to Acute Therapies 85 * Based on qualitative market research conducted by Santarus with physicians treating HAE patients. Patient preference will also influence treatment choice. ** Anabolic steroids Physicians' views of future distribution of treatments for HAE patien

  86. Slide 86: Ruconest

    86 Ruconest(r) No other marketed RECOMBINANT C1 esterase inhibitor products in U.S. Not plasma-derived Allows production of large quantities of complex protein Highly purified Approved for the treatment of acute attacks of HAE in Europe Orphan drug designation in U.S. (HAE acute treatment and prophy

  87. Slide 87: Ruconest Inhibits Multiple Cascades Involved in HAE

    Hereditary angioedema Complement cascade Coagulation cascade Ruconest(r) Inhibits Multiple Cascades Involved in HAE 87 Adapted from Morgan P. N Engl J Med. 2010; 363: 581-583 XII XIIa XI XIa IX Ixa (VIIIa) X Xa Prothrombin Thrombin Fibrinogen Fibrin Ruconest Ruconest C1r and C1s MASP-2 C2 C4 Rucones

  88. Slide 88: Ruconest Efficacy: Rapid Onset of Relief

    Ruconest(r) Efficacy: Rapid Onset of Relief and High Response Rate Within 4 Hours 88 Ruconest: Time to Onset of Relief Zuraw B, Cicardi M et al., J Allergy Clin Immunol 2010;126:821-827 Efficacy of C1 Inhibitors: Dose Matters Hack CE et al., Allergy 2012; 67:123-130 pdC1IHN (U/kg) rhC1INH (U/kg)

  89. Slide 89: Ruconest Positive Phase III Data

    Ruconest(r) - Positive Phase 3 Data for 50 U/kg Study 1310 Results Study 1310 Results Study 1310 Results Study 1310 Results Intent-to-Treat Population (N=75) Ruconest 50 U/kg (n = 44) Saline (n = 31) P-value Median time to the beginning of symptom relief (Primary Endpoint) (Based on Treatment Effect

  90. Slide 90: Time to Onset of Symptom Relief Across RCTs

    Study Dose Median Time (minutes) Median Time (minutes) P-value Study Dose Ruconest Saline P-value C1 1205 RCT (N=38) 100 U/kg 68 (62, 132) 258 (240, 495) P=0.001 C1 1205 RCT (N=38) 50 U/kg 122 (72, 136) 258 (240, 495) P<0.001 C1 1304 RCT (N=32) 100 U/kg 64 (40, 123) 520 (480, 720) P=0.004 C1 1310 RC

  91. Slide 91: Consistent Ruconest Efficacy Demonstrated in RCTs

    Time to Onset of Symptom Relief Assessed by VAS - Consistent Ruconest(r) Efficacy Demonstrated in RCTs 91

  92. Slide 92: Ruconest vs Other HAE Products

    92 Ruconest (r) (Investigational Drug) Cinryze(r) Berinert(r) Kalbitor(r) Firazyr(r) Indication Acute Prophylaxis Acute Acute Acute Dosing (U/kg) 50 U/kg 1000 U (~13 U/kg) 20 U/kg N/A N/A Safety Recombinant 1 case (0.4%) of anaphylaxis (N=236) No thromboembolic (TE) events reported Plasma derived TE

  93. Slide 93: C1 Inhibitor for HAE Prophylaxis

    C1 Inhibitor for HAE Prophylaxis 93 Twice weekly C1 inhibitor (Cinryze(r)) shown to reduce HAE attacks by ~ 50%1 Specific mechanism by which prophylactic C1INH therapy reduces the frequency of HAE attacks is not known No apparent correlation between attack frequency and C1INH plasma levels No thresh

  94. Slide 94: Rationale for Ruconest in HAE Prophylaxis

    Rationale for Ruconest(r) in HAE Prophylaxis *Reshef A, Moldovan D, Obtulowicz K et al. Allergy 2013;68(1):118-124 94 Open label Ruconest(r) study suggested benefit of once weekly dosing at 50 U/kg* N=25 patients Historical attack rate: Mean of 0.9 and median of 0.6 attacks per week Breakthrough att

  95. Slide 95: C1 Inhibitor - Many Potential Applications

    C1 Inhibitor - Many Potential Applications 95 Serine protease inhibitor (Serpin) Regulates complement and contact systems Inflammation Vascular permeability Pain Protease-independent anti-inflammatory functions Studies in animals and/or humans Capillary/vascular leak Pancreatitis, severe burns, seps

  96. Slide 96: Acute Pancreatitis - Overview

    Acute Pancreatitis - Overview *Peery A, Dellon E et al. Gastroenterology 2012;143: 1179-1187 96 Acute inflammation of the pancreas Most cases caused by gallstones (~40%) and alcohol consumption (~35%) Abdominal trauma, drugs, infection, endoscopic retrograde cholangiopancreatography (ERCP) procedure

  97. Slide 97: Acute Pancreatitis - Diagnosis and Classification

    Acute Pancreatitis - Diagnosis and Classification Diagnosis (two of three features) Abdominal pain Serum lipase or amylase ^ 3 times upper limit of normal Characteristic findings on imaging study (CT, MRI or ultrasound) Revised Atlanta Classification of Acute Pancreatitis (2012)* Categories: interst

  98. Slide 98: Acute Pancreatitis: Sequential Pathophysiological Process

    Acute Pancreatitis: Sequential Pathophysiological Process Inciting Event 98

  99. Slide 99: Duration of Symptoms Impacts Effect of Intervention

    Duration of Symptoms Impacts Effect of Intervention Relative Incidence ER Presentation Cytokine Production Organ Dysfunction 12 24 36 48 60 72 84 96 108 Hours After Onset of Pain Adapted from Norman J. Am J Surg. 1998; 175: 76-83 Interventional Window 99

  100. Slide 100: Prior Evidence of C1INH Benefit

    Prevention of elevated serum amylase levels induced by endoscopic sphincterotomy1 Forty patients randomized to C1INH or placebo 70% of patients in C1INH group had normal or decreased serum amylase vs. 15% of placebo patients Benefit in treatment of severe capillary leakage syndrome (CLS) following b

  101. Slide 101: Therapeutic Rationale for Ruconest in Acute Pancreatitis

    Therapeutic Rationale for Ruconest(r) in Acute Pancreatitis Acute pancreatitis is associated with the activation of the complement cascade and the contact (kallikrein-kinin) system C1INH inhibits the complement system Anti-inflammatory benefits C1INH also inhibits contact system proteases involved i

  102. Slide 102: Ruconest Summary

    Ruconest(r) Summary Successful completion of Phase III clinical study under Special Protocol Assessment (SPA) in acute treatment of HAE BLA submission planned in 2Q 2013 Potential for additional indications Plan to discuss SPA for HAE prophylaxis with FDA Expect to discuss clinical study for acute p

  103. Slide 103: Wrap-up/Question & Answer Session

    Wrap-up/Question & Answer Session Gerald T. Proehl President, Chief Executive Officer & Director Santarus, Inc.

  104. Slide 104: 2013 Planned Milestones

    2013 Planned Milestones 104 ?FDA approval for Uceris(tm) 1/14/13 ?Uceris commercial launch 2/14/13 Submit BLA for Ruconest(r) in HAE 2Q 2013 Complete enrollment in Uceris Phase IIIb study Mid-2013 Initiate SAN-300 Phase IIa study in RA patients 4Q 2013 Initiate proof-of-concept study with Ruconest i

  105. Slide 105: Investment Highlights

    Investment Highlights Profitable specialty biopharmaceutical company with a focus on proprietary products Attractive mix of commercial and development opportunities Recent launch of Uceris(tm) (budesonide) for induction of remission in patients with active, mild to moderate ulcerative colitis Court

  106. Slide 106: Additional Information

    Additional Information

  107. Slide 107: Uceris Important Safety Information

    Uceris(tm) Important Safety Information CONTRAINDICATIONS Uceris is contraindicated in patients with known hypersensitivity to budesonide or any of the ingredients of Uceris. WARNINGS AND PRECAUTIONS Hypercorticism and adrenal suppression. Risk of impaired adrenal function when transferring from ora

  108. Slide 108: Zegerid Important Safety Information

    Zegerid(r) Important Safety Information 108 CONTRAINDICATIONS Zegerid is contraindicated in patients with known hypersensitivity to any components of the formulation. WARNINGS AND PRECAUTIONS Concomitant Gastric Malignancy: Symptomatic response to therapy with Zegerid does not preclude the presence

  109. Slide 109: Glumetza Black Box Warning: Lactic Acidosis

    BLACK BOX WARNING: LACTIC ACIDOSIS Lactic Acidosis is a rare, but serious, complication that can occur due to metformin accumulation. The risk increases with conditions such as sepsis, dehydration, excess alcohol intake, hepatic insufficiency, renal impairment, and acute congestive heart failure. If

  110. Slide 110: Cycloset Important Safety Information

    Cycloset(r) Important Safety Information CONTRAINDICATIONS Cycloset is contraindicated in: Patients with known hypersensitivity to bromocriptine, ergot-related drugs, or any of the excipients in Cycloset; Patients with syncopal migraine; Women who are nursing their children. WARNINGS AND PRECAUTIONS

  111. Slide 111: Fenoglide Important Safety Information

    Fenoglide(r) Important Safety Information CONTRAINDICATIONS Fenoglide is contraindicated in patients: with severe renal dysfunction, including patients receiving dialysis, with active liver disease, with gallbladder disease, who are nursing mothers, with known hypersensitivity to fenofibrate. WARNIN

  112. Slide 112: Reconciliation of GAAP Net Income to Adjusted EBITDA - 4Q 2012 and 2011

    Reconciliation of GAAP Net Income to Adjusted EBITDA (Unaudited) - 4Q 2012 and 2011 ($ Millions) Three Months Ended Three Months Ended Three Months Ended December 31, December 31, December 31, 2012 2011 GAAP net income $ 5.5 $ 1.9 Interest (income) expense 0.1 0.1 Income tax expense 0.5 0.1 Deprecia

  113. Slide 113: Reconciliation of GAAP Net Income to Adjusted EBITDA 2010-2012

    Reconciliation of GAAP Net Income to Adjusted EBITDA in 2010-2012 Financial Results (Unaudited) Years Ended December 31, Years Ended December 31, Years Ended December 31, Years Ended December 31, Years Ended December 31, ($ Millions) 2012 2011 2010 GAAP net income (loss) $ 18.6 $ 4.7 $ (18.5) Intere

  114. Slide 114: Reconciliation of GAAP Net Income to Non-GAAP Adjusted Earnings Guidance 2013

    Reconciliation of GAAP Net Income to Non-GAAP Adjusted Earnings Guidance for the Year Ending December 31, 2013 114 GAAP net income GAAP net income $50 - $54 Interest (income) expense 0 Income tax expense 4 Depreciation and amortization 7 - 8 Stock-based compensation 12 - 13 Non-GAAP adjusted earning

Santarus — Investor Day (April 2013) on 6ix